病态肥胖患者初次与翻修全关节置换术中阿司匹林用于静脉血栓栓塞预防
单中心研究纳入2016至2022年BMI>40行初次与翻修全关节置换术的患者4672例,按BMI 40-44.9、45-49.9、50+分组,90天内总VTE率为0.4%,各组间无统计学差异;阿司匹林325mg、81mg、阿司匹林+抗凝药及单用抗凝药组VTE率无统计学差异,伤口并发症亦无显著差异。作者认为BMI>40患者使用阿司匹林是VTE预防的安全选择,并应在考虑患者其他VTE危险因素的背景下处方。
要点
- BMI>40行初次与翻修全关节置换术患者90天内总VTE率为0.4%(n=21)。
- BMI 40-44.9、45-49.9、50+三组VTE率分别为0.4%、0.4%、0.7%,无统计学差异(P=.669)。
- 阿司匹林325mg、81mg、阿司匹林+抗凝药、单用抗凝药组VTE率无统计学差异(P=.954)。
核心结论
- 作者认为,在BMI>40患者中,使用阿司匹林是VTE预防的安全选择,并应在考虑患者其他VTE危险因素的背景下处方。
研究设计与样本
- 单中心学术三级医疗中心研究,纳入2016至2022年BMI>40行初次与翻修全关节置换术的患者共4672例。
- 按BMI分组:40-44.9组3462例、45-49.9组935例、50+组275例。
- 主要结局为术后90天内任何VTE事件,次要结局为术后90天内伤口并发症。
主要发现
- 总VTE率为0.4%(n=21),BMI 40-44.9组0.4%、45-49.9组0.4%、50+组0.7%,三组间无统计学差异(P=.669)。
- VTE事件包括6例深静脉血栓、14例肺栓塞和1例深静脉血栓合并肺栓塞。
- 阿司匹林325mg组VTE率0.5%(n=9)、阿司匹林81mg组0.2%(n=1)、阿司匹林+抗凝药组0.5%(n=6)、单用抗凝药组0.4%(n=5),各组间无统计学差异(P=.954)。
- 阿司匹林325mg组、阿司匹林81mg组、阿司匹林+抗凝药组、单用抗凝药组伤口并发症率分别为1.6%、1.0%、1.8%、1.1%,无显著差异(P=.351)。
临床怎么用
- 作者认为,在BMI>40患者中,使用阿司匹林是VTE预防的安全选择,并应在考虑患者其他VTE危险因素的背景下处方。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) poses a major clinical concern due to its life-threatening nature, and obese and morbidly obese patients are thought to be at an increased risk for VTE. The aims of this study were twofold; first, to explore VTE rates in patients who have a body mass index (BMI) > 40 undergoing primary and revision total joint arthroplasty, and second, to investigate aspirin (ASA) efficacy and safety. METHODS: We identified all patients (n = 4,672) who had a BMI > 40 who underwent primary and revision total joint arthroplasty from 2016 to 2022 at a single academic tertiary care center. Patients were stratified by BMI groups: 40 to 44.9 (n = 3,462), 45 to 49.9 (n = 935), and 50+ (n = 275). The primary outcome was any VTE event within 90 days postoperatively. The secondary outcome consisted of wound complications within 90 days postoperatively. RESULTS: The total VTE rate was 0.4% (n = 21) and did not differ statistically between the BMI groups (0.4 versus 0.4 versus 0.7%, P = .669). The VTEs consisted of 6 deep venous thromboses (DVTs), 14 pulmonary embolisms, and one concomitant deep venous thrombosis and pulmonary embolism. The VTE rates were not statistically different between patients who received aspirin 325 mg 0.5% (n = 9), aspirin 81 mg 0.2% (n = 1), aspirin + anticoagulant (AC) 0.5% (n = 6), and AC alone 0.4% (n = 5) (P = .954). In addition, wound complications did not differ significantly between patients who received ASA 325 mg, ASA 81mg, ASA + AC, or AC alone (1.6 versus 1.0 versus 1.8 versus 1.1%, P = .351). CONCLUSIONS: The use of aspirin 325 and 81 mg was found to have similar VTE rates as aspirin + ACs and ACs alone, with no significant increase in wound complications. In patients who have a BMI > 40, the use of aspirin is a safe option for VTE prophylaxis and should be prescribed in the context of the patient who has other risk factors for VTE.
引用
- Torres-Ramirez RJ, Escalera C, Cushner FD, et al. The Use of Aspirin for Venous Thromboembolism Prophylaxis in Patients Who Have Morbid Obesity Undergoing Primary and Revision Total Joint Arthroplasty. J Arthroplasty. 2024. PMID: 38797448. doi:10.1016/j.arth.2024.05.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。